These findings, when amalgamated with gene expression profiling, suggest the activation of the KRAS and PI3K survival pathways and the deactivation of tumor suppressor genes PTEN and ARID1A in clear cell and endometrioid ovarian cancers. This evidence concerns the gene KRAS and neoplasm.